Dr. Caiwen Du 杜彩文
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology, with a focus on chemotherapy.
Dr. Du holds an MD and has worked in tumor chemotherapy for over ten years. Dr. Du graduated from Suzhou Medical College in 1994 and completed doctoral studies at Shantou University Medical College in 2006. Dr. Du received the Guangdong Province "Nanyue Outstanding Graduate Student Award" twice and has published several papers, including four indexed by SCI.
Name order: in Chinese the family name comes first (Du Caiwen). Papers usually list the name as Caiwen Du or Du C.
Selected publications
27 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2026 (senior author): Combination of vinorelbine capsules and the small molecule anti-angiogenic drug apatinib for first-line treatment of advanced triple-negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. PubMed 42798849
- Ther Adv Med Oncol, 2026 (senior author): Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study. PubMed 42539852
- Transl Cancer Res, 2026 (senior author): Utidelone exhibits favorable responses in refractory patients with advanced breast cancer. PubMed 42305475
- Cancer Med, 2026 (senior author): Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. PubMed 41834031
- Breast Cancer (Dove Med Press), 2025 (senior author): Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study. PubMed 41488682
- Breast Cancer (Dove Med Press), 2025 (senior author): Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. PubMed 41328430
- Breast Cancer (Dove Med Press), 2025 (senior author): Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer. PubMed 40606069
- Cancer Control, 2025 (senior author): Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study. PubMed 39754336
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion